Al-Jedai Ahmed Hamdan, Lomas James, Almudaiheem Hajer Yousef, Al-Ruthia Yazed Sulaiman H, Alghamdi Shabab, Awad Nancy, Alghamdi Ahlam, Alowairdhi Mohammad A, Alabdulkarim Hana, Almadi Majid, Bunyan Reem F, Ochalek Jessica
Therapeutic Affairs, Ministry of Health Saudi Arabia, Riyadh, Saudi Arabia.
Colleges of Pharmacy and Medicine, Alfaisal University, Riyadh, Saudi Arabia.
J Med Econ. 2023 Jan-Dec;26(1):128-138. doi: 10.1080/13696998.2022.2157141.
Saudi Arabia's Vision 2030 aims to reform health care across the Kingdom, with health technology assessment being adopted as one tool promising to improve the efficiency with which resources are used. An understanding of the opportunity costs of reimbursement decisions is key to fulfilling this promise and can be used to inform a cost-effectiveness threshold. This paper is the first to provide a range of estimates of this using existing evidence extrapolated to the context of Saudi Arabia.
We use four approaches to estimate the marginal cost per unit of health produced by the healthcare system; drawing from existing evidence provided by a cross-country analysis, two alternative estimates from the UK context, and based on extrapolating a UK estimate using evidence on the income elasticity of the value of health. Consequences of estimation error are explored.
Based on the four approaches, we find a range of SAR 42,046 per QALY gained (48% of GDP per capita) to SAR 215,120 per QALY gained (246% of GDP per capita). Calculated potential central estimates from the average of estimated health gains based on each source gives a range of SAR 50,000-75,000. The results are in line with estimates from the emerging literature from across the world.
A cost-effectiveness threshold reflecting health opportunity costs can aid decision-making. Applying a cost-effectiveness threshold based on the range SAR 50,000 to 75,000 per QALY gained would ensure that resource allocation decisions in healthcare can in be informed in a way that accounts for health opportunity costs.
A limitation is that it is not based on a within-country study for Saudi Arabia, which represents a promising line of future work.
沙特阿拉伯的《2030年愿景》旨在对沙特全国的医疗保健进行改革,将卫生技术评估作为有望提高资源利用效率的一种工具。理解报销决策的机会成本是兑现这一承诺的关键,并且可用于确定成本效益阈值。本文首次利用现有证据推断沙特阿拉伯的情况,给出了一系列对此的估计值。
我们采用四种方法来估计医疗保健系统产生的每单位健康产出的边际成本;借鉴跨国分析提供的现有证据、英国背景下的两种替代估计值,并根据健康价值的收入弹性证据推断英国的一项估计值。探讨了估计误差的影响。
基于这四种方法,我们发现每获得一个质量调整生命年的成本范围为42,046沙特里亚尔(人均国内生产总值的48%)至215,120沙特里亚尔(人均国内生产总值的246%)。根据每种来源估计的健康收益平均值计算出的潜在中心估计值范围为50,000 - 75,000沙特里亚尔。结果与世界各地新出现的文献中的估计值一致。
反映健康机会成本的成本效益阈值有助于决策。应用基于每获得一个质量调整生命年50,000至75,000沙特里亚尔范围的成本效益阈值,将确保医疗保健中的资源分配决策能够以考虑健康机会成本的方式做出。
一个局限性是它并非基于沙特阿拉伯国内的研究,这是未来一项有前景的工作方向。